GlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.).
GlaxoSmithKline, Collegeville, Pennsylvania (N.M., K.K.P., J.M.M., S.C., J.W.P., A.D.W.); Lawrence Livermore National Laboratory, Livermore, California (A.M.); Frederick National Laboratory for Cancer Research, Frederick, Maryland (B.D.M.); and Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, San Francisco, California (N.M., K.K.P., B.D.M., A.M., J.M.M., S.C., J.W.P., A.D.W.)
Drug Metab Dispos. 2021 Feb;49(2):169-178. doi: 10.1124/dmd.120.000202. Epub 2020 Nov 25.
Volume of distribution at steady state (V) is one of the key pharmacokinetic parameters estimated during the drug discovery process. Despite considerable efforts to predict V, accuracy and choice of prediction methods remain a challenge, with evaluations constrained to a small set (<150) of compounds. To address these issues, a series of in silico methods for predicting human V directly from structure were evaluated using a large set of clinical compounds. Machine learning (ML) models were built to predict V directly and to predict input parameters required for mechanistic and empirical V predictions. In addition, log D, fraction unbound in plasma (fup), and blood-to-plasma partition ratio (BPR) were measured on 254 compounds to estimate the impact of measured data on predictive performance of mechanistic models. Furthermore, the impact of novel methodologies such as measuring partition (Kp) in adipocytes and myocytes ( = 189) on V predictions was also investigated. In predicting V directly from chemical structures, both mechanistic and empirical scaling using a combination of predicted rat and dog V demonstrated comparable performance (62%-71% within 3-fold). The direct ML model outperformed other in silico methods (75% within 3-fold, = 0.5, AAFE = 2.2) when built from a larger data set. Scaling to human from predicted V of either rat or dog yielded poor results (<47% within 3-fold). Measured fup and BPR improved performance of mechanistic V predictions significantly (81% within 3-fold, = 0.6, AAFE = 2.0). Adipocyte intracellular Kp showed good correlation to the V but was limited in estimating the compounds with low V SIGNIFICANCE STATEMENT: This work advances the in silico prediction of V directly from structure and with the aid of in vitro data. Rigorous and comprehensive evaluation of various methods using a large set of clinical compounds ( = 956) is presented. The scale of techniques evaluated is far beyond any previously presented. The novel data set ( = 254) generated using a single protocol for each in vitro assay reported in this study could further aid in advancing V prediction methodologies.
在药物发现过程中,稳态分布容积 (V) 是估算的关键药代动力学参数之一。尽管人们付出了相当大的努力来预测 V,但预测的准确性和方法的选择仍然是一个挑战,评估受到化合物数量限制(<150)。为了解决这些问题,使用一组大的临床化合物评估了一系列可直接从结构预测人体 V 的计算方法。构建了机器学习 (ML) 模型,以直接预测 V,并预测机械和经验 V 预测所需的输入参数。此外,在 254 种化合物上测量了 log D、血浆中未结合分数 (fup) 和血液与血浆分配比 (BPR),以估计实测数据对机械模型预测性能的影响。此外,还研究了新型方法的影响,例如测量脂肪细胞和肌细胞中的分配 (Kp)(= 189)对 V 预测的影响。从化学结构直接预测 V 时,使用预测的大鼠和狗 V 的组合进行机械和经验比例,表现出相当的性能(3 倍内 62%-71%)。直接 ML 模型从更大的数据集构建时,优于其他计算方法(3 倍内 75%,= 0.5,AAFE = 2.2)。从大鼠或狗预测的 V 扩展到人体,结果较差(3 倍内<47%)。实测 fup 和 BPR 显著提高了机械 V 预测的性能(3 倍内 81%,= 0.6,AAFE = 2.0)。脂肪细胞内 Kp 与 V 有很好的相关性,但在估计 V 较低的化合物时受到限制。